Insight

María Natalia Gandur Quiroga: NECTIN4 Amplification Predicts Enfortumab Vedotin Response in mUC by Niklas Klümper et al.

Collage photo of María Natalia Gandur Quiroga and Niklas Klümper

Dec 18, 2024, 12:55

María Natalia Gandur Quiroga: NECTIN4 Amplification Predicts Enfortumab Vedotin Response in mUC by Niklas Klümper et al.

María Natalia Gandur Quiroga, Medical Oncologist and Chief of the Division of Genitourinary Medical Oncology at the Ángel H. Roffo Oncology Institute in Buenos Aires, Argentina, shared a post on X, about a paper by Niklas Klümper et al. published in Journal of Clinical Oncology.

“NECTIN4 Amplification Predicts Enfortumab Vedotin Response in mUC.

Key finding: NECTIN4 amplification predicts a 96% objective response to Enfortumab Vedotin (EV) in metastatic urothelial cancer (mUC).
Survival: NECTIN4 amplification reduces the risk of death by 92% (HR: 0.08; p<0.001).
Tumor biology: Amplified NECTIN4 maintains high protein expression during metastatic progression.
Pan-cancer: Found in 5-10% of breast, lung, and other cancers, broadening EV’s potential in tumor-agnostic contexts.”

“NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer”

Authors: Niklas Klümper, Ngoc Khanh Tran, Stefanie Zschäbitz, Michael Hölzel, Markus Eckstein et al.

María Natalia Gandur Quiroga: NECTIN4 Amplification Predicts Enfortumab Vedotin Response in mUC by Niklas Klümper et al.

More posts featuring María Natalia Gandur Quiroga and Niklas Klümper.

María Natalia Gandur Quiroga is a Medical Oncologist and Chief of the Division of Genitourinary Medical Oncology at the Ángel H. Roffo Oncology Institute in Buenos Aires, Argentina. She is a Professor of Medicine at the University of Buenos Aires at the Oncologists Post Graduates Studies.

Her research focuses on clinical trials with aims to improve the treatment of patients with urologic tumors. She is an active member of the European Association for Cancer Research, Argentinian Medical Association and American Society of Clinical Oncology.

Niklas Klümper, MD, is a senior urology consultant specializing in genitourinary (GU) oncology and an advanced clinician-scientist at the University Medical Center Bonn (UKB), supported by the BMBF-funded ACCENT program.

He leads a translational uro-oncology research group that bridges the Department of Urology and the Institute of Experimental Oncology. His research focuses on improving treatment response predictions for targeted therapies, developing personalized treatment strategies, and conducting clinical trials to enhance outcomes for patients with uro-oncological diseases.